Tracking side effects of T-DXd for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at people with advanced breast cancer who will receive a drug called T-DXd. Researchers want to understand the side effects of this treatment by analyzing blood samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with advanced breast cancer that has spread beyond the breast.
- Your cancer must be either HER2-positive or HER2-low/ultralow (levels of a protein on cancer cells).
- Your doctor has decided to treat you with T-DXd as part of your normal care.
- You agree to give extra blood samples for research purposes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
This study looks at a protein called GDF-15 in the blood and how it relates to side effects like weight loss during treatment with the drug T-DXd for advanced breast cancer. By joining, you help researchers learn more about managing these side effects.
This trial studies how the drug T-DXd (trastuzumab-deruxtecan) works in people with advanced or metastatic breast cancer. It compares drug levels in the body based on body mass index (BMI) to see if dose adjustments are needed.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.